Eli Lilly, a global pharmaceutical company, announced the launch of Copellor®(Ixekizumab) in India. The drug has received approval from The Drug Controller General of India (DCGI) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, as well as for the treatment of adult patients with active psoriatic arthritis. Copellor®(Ixekizumab) is a humanized IgG4 monoclonal antibody that specifically targets IL-17A, a protein responsible for triggering and maintaining inflammation in psoriasis.
The impact of psoriasis on a patient’s quality of life is comparable to that of serious diseases such as cancer and heart failure, according to global studies. The availability of Copellor®(Ixekizumab) will now provide healthcare providers with another option for treating adults with moderate-to-severe plaque psoriasis and adult patients with active psoriatic arthritis, a huge unmet need in India. Vineet Gupta, Managing Director, Eli Lilly and Company – India & India Subcontinent, said that their foray into the dermatology segment strengthens Lilly’s promise of bringing innovative medicines to India.
Copellor®(Ixekizumab) is a prescription medicine available in one strength of 80 mg/ml in a single-dose prefilled autoinjector. It is recommended to be used only on the advice of a dermatologist or rheumatologist and under medical supervision. The launch of Copellor®(Ixekizumab) reinforces Eli Lilly’s commitment to improving patient outcomes and quality of life through innovative treatments in India.
Overall, the launch of Copellor®(Ixekizumab) by Eli Lilly in India provides a new treatment option for adults with moderate-to-severe plaque psoriasis and adult patients with active psoriatic arthritis. The drug specifically targets the protein responsible for triggering and maintaining inflammation in psoriasis, providing healthcare providers with an additional tool to help improve patient outcomes. The launch is also a testament to Eli Lilly’s commitment to bringing innovative treatments to India and improving patient quality of life.